Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | USP2 | O75604 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | RECQL | P46063 | 3/20 | 0.70 |
| ▸ | BLM | P54132 | 3/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213665 | 1.00 | EGFR (0.70) | EGFRERBB2ALDH1A1MAPTKDM4E | |
| SCHEMBL6213658 | 1.00 | EGFR (0.70) | EGFRERBB2ALDH1A1MAPTKDM4E | |
| SCHEMBL30549409 | 1.00 | EGFR (0.70) | EGFRERBB2ALDH1A1MAPTKDM4E | |
| SCHEMBL29429711 | 0.84 | EGFR (1.00) | EGFRERBB2ALDH1A1MAPTKDM4E | |
| SCHEMBL2678765 | 0.84 | EGFR (1.00) | EGFRERBB2ALDH1A1MAPTKDM4E | |
| SCHEMBL2678764 | 0.84 | EGFR (1.00) | EGFRERBB2ALDH1A1MAPTKDM4E | |
| SCHEMBL2678762 | 0.84 | EGFR (1.00) | EGFRERBB2ALDH1A1MAPTKDM4E | |
| SCHEMBL17480115 | 0.80 | ALDH1A1 (0.67) | EGFRALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL16627347 | 0.80 | ALDH1A1 (0.67) | EGFRALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL14682582 | 0.79 | MAPT (0.74) | EGFRERBB2ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5981569-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-11-09 | — | — | US | claimed |
| EP-0527181-A4 | HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | — | 1993-04-07 | — | — | EP | claimed |
| US-5196446-A | Treatment of psoriasis, atherosclerosis | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-03-23 | — | — | US | claimed |
| EP-0527181-A1 | HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-02-17 | — | — | EP | claimed |
| WO-1991016305-A1 | HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-10-31 | — | — | WO | claimed |
| EP-0748219-B8 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-0748219-B1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-5981569-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-11-09 | — | — | US | disclosed |
| EP-0748219-A4 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5849742-A | Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis | SUGEN INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5792771-A | FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5763441-A | ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS | SUGEN, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5712395-A | BENZO(G)QUINOXALINE | YISSUM RESEARCH DEVELOPMENT CORP. (IL) | 1998-01-27 | — | — | US | disclosed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0527181-A4 | HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | — | 1993-04-07 | — | — | EP | disclosed |
| US-5196446-A | Treatment of psoriasis, atherosclerosis | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-03-23 | — | — | US | disclosed |
| EP-0527181-A1 | HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-02-17 | — | — | EP | disclosed |
| WO-1991016305-A1 | HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-10-31 | — | — | WO | disclosed |